Company news

Acumen Pharmaceuticals, Inc. news in 2025

Acumen Pharmaceuticals, Inc.'s news releases, calls and decks from 2025, newest first.

View company

Acumen Pharmaceuticals Highlights Enhanced Brain Delivery™ Technology for Oligomer-Selective Antibodies and Recruitment Strategies for Phase 2 ALTITUDE-AD Clinical Trial at 18th Annual Clinical Trials on Alzheimer’s Disease (CTAD) Conference

December 2, 2025

Acumen Pharmaceuticals to Present on Recruitment Strategies for Phase 2 ALTITUDE-AD Trial and Enhanced Brain Delivery Technology at 18th Annual Clinical Trials on Alzheimer’s Disease (CTAD) Conference

November 18, 2025

Acumen Pharmaceuticals Announces First Participant Dosed in Phase 2 Open-Label Extension Study of Sabirnetug in People with Early Alzheimer’s Disease

November 17, 2025

Acumen Pharmaceuticals Reports Third Quarter 2025 Financial Results and Business Highlights

November 12, 2025

Acumen Pharmaceuticals Appoints George Golumbeski, Ph.D., as Chairman of its Board of Directors

November 10, 2025

Acumen Pharmaceuticals to Report Third Quarter 2025 Financial Results on November 12, 2025

November 5, 2025

Acumen Pharmaceuticals to Participate in the Stifel Healthcare Conference

November 4, 2025

Acumen Pharmaceuticals to Participate in Upcoming Investor Conferences

August 26, 2025

Acumen Pharmaceuticals Reports Second Quarter 2025 Financial Results and Business Highlights

August 12, 2025

Acumen Pharmaceuticals to Report Second Quarter 2025 Financial Results on August 12, 2025

August 5, 2025

Acumen Pharmaceuticals Presents Studies Showing the Utility of a pTau217 Assay in Screening for a Phase 2 Alzheimer’s Disease Trial and Validates Sabirnetug Oligomer-Selectivity, at the Alzheimer’s Association International Conference (AAIC) 2025

July 28, 2025

JCR Pharmaceuticals and Acumen Pharmaceuticals Announce Collaboration to Develop Therapy for Alzheimer’s Disease, Enabled by J-Brain Cargo® Technology Platform

July 15, 2025

Acumen Pharmaceuticals and JCR Pharmaceuticals Enter Strategic Collaboration, Option and License Agreement to Develop Enhanced Brain Delivery™ Therapy for Alzheimer’s Disease

July 15, 2025

Acumen Pharmaceuticals to Present Studies on Cost Savings Associated with Use of pTau217 Screening Assay in Phase 2 ALTITUDE-AD Study and Sabirnetug Oligomer-Selectivity at the Alzheimer’s Association International Conference (AAIC®) 2025

July 10, 2025

Acumen Pharmaceuticals Reports First Quarter 2025 Financial Results and Business Highlights

May 13, 2025

Acumen Pharmaceuticals to Participate in the Bank of America Healthcare Conference

May 7, 2025

Acumen Pharmaceuticals to Report First Quarter 2025 Financial Results on May 13, 2025

May 6, 2025

Acumen Pharmaceuticals Showcases pTau217 Trial Screening Progress in Phase 2 ALTITUDE-AD Trial and Preclinical Research Methods at AD/PD 2025 and AAN Annual Meeting

April 2, 2025

Acumen Pharmaceuticals Reports Financial Results for the Year Ended December 31, 2024 and Business Highlights

March 27, 2025

Acumen Pharmaceuticals Completes Enrollment of ALTITUDE-AD, a Phase 2 Clinical Trial of Sabirnetug (ACU193) in Early Alzheimer’s Disease

March 26, 2025

Acumen Pharmaceuticals to Report Fourth Quarter and Year-End 2024 Financial Results on March 27, 2025

March 20, 2025

Acumen Pharmaceuticals Announces Topline Results from Phase 1 Study of Subcutaneous Formulation of Sabirnetug in Healthy Volunteers

March 19, 2025

Acumen Pharmaceuticals CEO Discusses Novel Targeted Therapies for Alzheimer’s

March 18, 2025

Acumen Pharmaceuticals to Present During International Conference on Alzheimer’s and Parkinson’s Diseases 2025 and American Academy of Neurology Annual Meeting

March 12, 2025

Acumen Pharmaceuticals Announces Journal of Prevention of Alzheimer’s Disease Publication of the Company’s Phase 1 INTERCEPT-AD Study, Including Target Engagement, Dosing Regimen and Safety Findings

January 8, 2025

Calls in 2025

Decks in 2025